* TELA Bio Inc TELA.OQ TELA.O is expected to show a rise
in
quarterly revenue when it reports results on May 10.
* The Malvern Pennsylvania-based company is expected to
report a
35.3% increase in revenue to $7.953 million from $5.88 million a
year ago, according to the mean estimate from 4 analysts, based
on Refinitiv data.
* Refinitiv's mean analyst estimate for TELA Bio Inc is for
a
loss of 56 cents per share. For the same quarter last year, the
company reported a loss of 56 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for TELA Bio
Inc is
$20, above its last closing price of $9.40.
* Previous quarterly performance (using preferred earnings
measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2021 -0.55 -0.59 Missed -7.8
Sep. 30 2021 -0.54 -0.52 -0.57 Missed -8.6
Jun. 30 2021 -0.53 -0.52 -0.57 Missed -9.6
Mar. 31 2021 -0.49 -0.48 -0.56 Missed -16.1
Dec. -0.42 -0.49 -0.54 Missed -10.7
31 2020
Sep. 30 2020 -0.49 -0.49 -0.53 Missed -9.2
Jun. 30 2020 -0.59 -0.59 -0.53 Beat 9.8
Mar. 31 2020 -0.56 -0.56 -0.63 Missed -12
This summary was machine generated May 7 at 02:05 GMT. All
figures in US dollars unless otherwise stated